<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24145533</PMID><DateCompleted><Year>2014</Year><Month>09</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1098-6596</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><Issue>1</Issue><PubDate><Year>2014</Year></PubDate></JournalIssue><Title>Antimicrobial agents and chemotherapy</Title><ISOAbbreviation>Antimicrob Agents Chemother</ISOAbbreviation></Journal><ArticleTitle>A novel dengue virus inhibitor, BP13944, discovered by high-throughput screening with dengue virus replicon cells selects for resistance in the viral NS2B/NS3 protease.</ArticleTitle><Pagination><StartPage>110</StartPage><EndPage>119</EndPage><MedlinePgn>110-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.01281-13</ELocationID><Abstract><AbstractText>Dengue virus (DENV) causes disease globally, resulting in an estimated 25 to 100 million new infections per year. No effective DENV vaccine is available, and the current treatment is only supportive. Thus, there is an urgent need to develop therapeutic agents to cure this epidemic disease. In the present study, we identified a potential small-molecule inhibitor, BP13944, via high-throughput screening (HTS) of 60,000 compounds using a stable cell line harboring an efficient luciferase replicon of DENV serotype 2 (DENV-2). BP13944 reduced the expression of the DENV replicon reporter in cells, showing a 50% effective concentration (EC50) of 1.03 &#xb1; 0.09 &#x3bc;M. Without detectable cytotoxicity, the compound inhibited replication or viral RNA synthesis in all four serotypes of DENV but not in Japanese encephalitis virus (JEV). Sequencing analyses of several individual clones derived from BP13944-resistant RNAs purified from cells harboring the DENV-2 replicon revealed a consensus amino acid substitution (E66G) in the region of the NS3 protease domain. Introduction of E66G into the DENV replicon, an infectious DENV cDNA clone, and recombinant NS2B/NS3 protease constructs conferred 15.2-, 17.2-, and 3.1-fold resistance to BP13944, respectively. Our results identify an effective small-molecule inhibitor, BP13944, which likely targets the DENV NS3 protease. BP13944 could be considered part of a more effective treatment regime for inhibiting DENV in the future.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Chi-Chen</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan Town, Miaoli, Taiwan, Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Han-Shu</ForeName><Initials>HS</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Ren-Huang</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Szu-Huei</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Shiow-Ju</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Jiaang</LastName><ForeName>Weir-Torn</ForeName><Initials>WT</Initials></Author><Author ValidYN="Y"><LastName>Chern</LastName><ForeName>Jyh-Haur</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Zhi-Shun</ForeName><Initials>ZS</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Huey-Nan</ForeName><Initials>HN</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Chung-Ming</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Yueh</LastName><ForeName>Andrew</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Antimicrob Agents Chemother</MedlineTA><NlmUniqueID>0315061</NlmUniqueID><ISSNLinking>0066-4804</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054852">Small Molecule Libraries</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="C504449">NS3 protease, dengue virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D012697">Serine Endopeptidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006224" MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D024882" MajorTopicYN="N">Drug Resistance, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012093" MajorTopicYN="N">Replicon</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012697" MajorTopicYN="N">Serine Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054852" MajorTopicYN="N">Small Molecule Libraries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>9</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24145533</ArticleId><ArticleId IdType="pmc">PMC3910792</ArticleId><ArticleId IdType="doi">10.1128/AAC.01281-13</ArticleId><ArticleId IdType="pii">AAC.01281-13</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gubler DJ, Kuno G, Markoff L. 2007. Flaviviruses, p 1153&#x2013;1253 In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE. (ed), Fields virology, 5th ed, vol 1 Lippincott Williams &amp; Wilkins, Philadelphia, PA</Citation></Reference><Reference><Citation>Ye J, Zhu B, Fu ZF, Chen H, Cao S. 2012. Immune evasion strategies of flaviviruses. Vaccine 31:461&#x2013;471. 10.1016/j.vaccine.2012.11.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.11.015</ArticleId><ArticleId IdType="pubmed">23153447</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization
2012. 
Dengue and severe dengue. World Health Organization, Geneva, Switzerland: 
http://www.who.int/mediacentre/factsheets/fs117/en/</Citation></Reference><Reference><Citation>World Health Organization
2009. 
Dengue: guidelines for diagnosis, treatment, prevention and control. World Health Organization, Geneva, Switzerland: 
http://whqlibdoc.who.int/publications/2009/9789241547871_eng.pdf</Citation></Reference><Reference><Citation>Halstead SB. 1980. Dengue haemorrhagic fever&#x2014;a public health problem and a field for research. Bull. World Health Organ. 58:1&#x2013;21</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2395896</ArticleId><ArticleId IdType="pubmed">6966540</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubler DJ. 1989. Aedes aegypti and Aedes aegypti-borne disease control in the 1990s: top down or bottom up. Charles Franklin Craig lecture. Am. J. Trop. Med. Hyg. 40:571&#x2013;578</Citation><ArticleIdList><ArticleId IdType="pubmed">2472746</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinheiro FP. 1989. Dengue in the Americas. 1980&#x2013;1987. Epidemiol. Bull. 10:1&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pubmed">2484241</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble CG, Chen YL, Dong H, Gu F, Lim SP, Schul W, Wang QY, Shi PY. 2010. Strategies for development of dengue virus inhibitors. Antiviral Res. 85:450&#x2013;462. 10.1016/j.antiviral.2009.12.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2009.12.011</ArticleId><ArticleId IdType="pubmed">20060421</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons CP, Farrar JJ, Nguyen v V, Wills B. 2012. Dengue. N. Engl. J. Med. 366:1423&#x2013;1432. 10.1056/NEJMra1110265</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1110265</ArticleId><ArticleId IdType="pubmed">22494122</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice CM, Lenches EM, Eddy SR, Shin SJ, Sheets RL, Strauss JH. 1985. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science 229:726&#x2013;733. 10.1126/science.4023707</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.4023707</ArticleId><ArticleId IdType="pubmed">4023707</ArticleId></ArticleIdList></Reference><Reference><Citation>Chambers TJ, Hahn CS, Galler R, Rice CM. 1990. Flavivirus genome organization, expression, and replication. Annu. Rev. Microbiol. 44:649&#x2013;688. 10.1146/annurev.mi.44.100190.003245</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.mi.44.100190.003245</ArticleId><ArticleId IdType="pubmed">2174669</ArticleId></ArticleIdList></Reference><Reference><Citation>Falgout B, Pethel M, Zhang YM, Lai CJ. 1991. Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J. Virol. 65:2467&#x2013;2475</Citation><ArticleIdList><ArticleId IdType="pmc">PMC240601</ArticleId><ArticleId IdType="pubmed">2016768</ArticleId></ArticleIdList></Reference><Reference><Citation>Kummerer BM, Rice CM. 2002. Mutations in the yellow fever virus nonstructural protein NS2A selectively block production of infectious particles. J. Virol. 76:4773&#x2013;4784. 10.1128/JVI.76.10.4773-4784.2002</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.76.10.4773-4784.2002</ArticleId><ArticleId IdType="pmc">PMC136122</ArticleId><ArticleId IdType="pubmed">11967294</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu WJ, Chen HB, Khromykh AA. 2003. Molecular and functional analyses of Kunjin virus infectious cDNA clones demonstrate the essential roles for NS2A in virus assembly and for a nonconservative residue in NS3 in RNA replication. J. Virol. 77:7804&#x2013;7813. 10.1128/JVI.77.14.7804-7813.2003</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.77.14.7804-7813.2003</ArticleId><ArticleId IdType="pmc">PMC161959</ArticleId><ArticleId IdType="pubmed">12829820</ArticleId></ArticleIdList></Reference><Reference><Citation>Patkar CG, Kuhn RJ. 2008. Yellow fever virus NS3 plays an essential role in virus assembly independent of its known enzymatic functions. J. Virol. 82:3342&#x2013;3352. 10.1128/JVI.02447-07</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02447-07</ArticleId><ArticleId IdType="pmc">PMC2268495</ArticleId><ArticleId IdType="pubmed">18199634</ArticleId></ArticleIdList></Reference><Reference><Citation>Best SM, Morris KL, Shannon JG, Robertson SJ, Mitzel DN, Park GS, Boer E, Wolfinbarger JB, Bloom ME. 2005. Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist. J. Virol. 79:12828&#x2013;12839. 10.1128/JVI.79.20.12828-12839.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.20.12828-12839.2005</ArticleId><ArticleId IdType="pmc">PMC1235813</ArticleId><ArticleId IdType="pubmed">16188985</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo JT, Hayashi J, Seeger C. 2005. West Nile virus inhibits the signal transduction pathway of alpha interferon. J. Virol. 79:1343&#x2013;1350. 10.1128/JVI.79.3.1343-1350.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.3.1343-1350.2005</ArticleId><ArticleId IdType="pmc">PMC544142</ArticleId><ArticleId IdType="pubmed">15650160</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu WJ, Wang XJ, Mokhonov VV, Shi PY, Randall R, Khromykh AA. 2005. Inhibition of interferon signaling by the New York 99 strain and Kunjin subtype of West Nile virus involves blockage of STAT1 and STAT2 activation by nonstructural proteins. J. Virol. 79:1934&#x2013;1942. 10.1128/JVI.79.3.1934-1942.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.3.1934-1942.2005</ArticleId><ArticleId IdType="pmc">PMC544092</ArticleId><ArticleId IdType="pubmed">15650219</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz-Jordan JL, Laurent-Rolle M, Ashour J, Martinez-Sobrido L, Ashok M, Lipkin WI, Garcia-Sastre A. 2005. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J. Virol. 79:8004&#x2013;8013. 10.1128/JVI.79.13.8004-8013.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.13.8004-8013.2005</ArticleId><ArticleId IdType="pmc">PMC1143737</ArticleId><ArticleId IdType="pubmed">15956546</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz-Jordan JL, Sanchez-Burgos GG, Laurent-Rolle M, Garcia-Sastre A. 2003. Inhibition of interferon signaling by dengue virus. Proc. Natl. Acad. Sci. U. S. A. 100:14333&#x2013;14338. 10.1073/pnas.2335168100</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2335168100</ArticleId><ArticleId IdType="pmc">PMC283592</ArticleId><ArticleId IdType="pubmed">14612562</ArticleId></ArticleIdList></Reference><Reference><Citation>Wengler G, Wengler G. 1991. The carboxy-terminal part of the NS 3 protein of the West Nile flavivirus can be isolated as a soluble protein after proteolytic cleavage and represents an RNA-stimulated NTPase. Virology 184:707&#x2013;715. 10.1016/0042-6822(91)90440-M</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0042-6822(91)90440-M</ArticleId><ArticleId IdType="pubmed">1716026</ArticleId></ArticleIdList></Reference><Reference><Citation>Falgout B, Miller RH, Lai CJ. 1993. Deletion analysis of dengue virus type 4 nonstructural protein NS2B: identification of a domain required for NS2B-NS3 protease activity. J. Virol. 67:2034&#x2013;2042</Citation><ArticleIdList><ArticleId IdType="pmc">PMC240272</ArticleId><ArticleId IdType="pubmed">8383225</ArticleId></ArticleIdList></Reference><Reference><Citation>Wengler G, Wengler G. 1993. The NS3 nonstructural protein of flaviviruses contains an RNA triphosphatase activity. Virology 197:265&#x2013;273. 10.1006/viro.1993.1587</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1993.1587</ArticleId><ArticleId IdType="pubmed">8212562</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazan JF, Fletterick RJ. 1989. Detection of a trypsin-like serine protease domain in flaviviruses and pestiviruses. Virology 171:637&#x2013;639. 10.1016/0042-6822(89)90639-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0042-6822(89)90639-9</ArticleId><ArticleId IdType="pubmed">2548336</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorbalenya AE, Donchenko AP, Koonin EV, Blinov VM. 1989. N-terminal domains of putative helicases of flavi- and pestiviruses may be serine proteases. Nucleic Acids Res. 17:3889&#x2013;3897. 10.1093/nar/17.10.3889</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/17.10.3889</ArticleId><ArticleId IdType="pmc">PMC317867</ArticleId><ArticleId IdType="pubmed">2543956</ArticleId></ArticleIdList></Reference><Reference><Citation>Valle RP, Falgout B. 1998. Mutagenesis of the NS3 protease of dengue virus type 2. J. Virol. 72:624&#x2013;632</Citation><ArticleIdList><ArticleId IdType="pmc">PMC109416</ArticleId><ArticleId IdType="pubmed">9420267</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu T, Sampath A, Chao A, Wen D, Nanao M, Chene P, Vasudevan SG, Lescar J. 2005. Structure of the dengue virus helicase/nucleoside triphosphatase catalytic domain at a resolution of 2.4 A. J. Virol. 79:10278&#x2013;10288. 10.1128/JVI.79.16.10278-10288.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.16.10278-10288.2005</ArticleId><ArticleId IdType="pmc">PMC1182654</ArticleId><ArticleId IdType="pubmed">16051821</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo D, Xu T, Hunke C, Gruber G, Vasudevan SG, Lescar J. 2008. Crystal structure of the NS3 protease-helicase from dengue virus. J. Virol. 82:173&#x2013;183. 10.1128/JVI.01788-07</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01788-07</ArticleId><ArticleId IdType="pmc">PMC2224403</ArticleId><ArticleId IdType="pubmed">17942558</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo D, Wei N, Doan DN, Paradkar PN, Chong Y, Davidson AD, Kotaka M, Lescar J, Vasudevan SG. 2010. Flexibility between the protease and helicase domains of the dengue virus NS3 protein conferred by the linker region and its functional implications. J. Biol. Chem. 285:18817&#x2013;18827. 10.1074/jbc.M109.090936</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.090936</ArticleId><ArticleId IdType="pmc">PMC2881804</ArticleId><ArticleId IdType="pubmed">20375022</ArticleId></ArticleIdList></Reference><Reference><Citation>Menendez-Arias L. 2010. Molecular basis of human immunodeficiency virus drug resistance: an update. Antiviral Res. 85:210&#x2013;231. 10.1016/j.antiviral.2009.07.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2009.07.006</ArticleId><ArticleId IdType="pubmed">19616029</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatraman S. 2012. Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections. Trends Pharmacol. Sci. 33:289&#x2013;294. 10.1016/j.tips.2012.03.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2012.03.012</ArticleId><ArticleId IdType="pubmed">22521415</ArticleId></ArticleIdList></Reference><Reference><Citation>Casey LC, Lee WM. 2013. Hepatitis C virus therapy update 2013. Curr. Opin. Gastroenterol. 29:243&#x2013;249. 10.1097/MOG.0b013e32835ff972</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOG.0b013e32835ff972</ArticleId><ArticleId IdType="pubmed">23563981</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks KM, Jacobson IM. 2012. The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir. Antivir. Ther. 17:1119&#x2013;1131. 10.3851/IMP2424</Citation><ArticleIdList><ArticleId IdType="doi">10.3851/IMP2424</ArticleId><ArticleId IdType="pubmed">23188750</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble CG, Shi PY. 2012. Structural biology of dengue virus enzymes: towards rational design of therapeutics. Antiviral Res. 96:115&#x2013;126. 10.1016/j.antiviral.2012.09.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2012.09.007</ArticleId><ArticleId IdType="pubmed">22995600</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampath A, Padmanabhan R. 2009. Molecular targets for flavivirus drug discovery. Antiviral Res. 81:6&#x2013;15. 10.1016/j.antiviral.2008.08.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2008.08.004</ArticleId><ArticleId IdType="pmc">PMC2647018</ArticleId><ArticleId IdType="pubmed">18796313</ArticleId></ArticleIdList></Reference><Reference><Citation>Lescar J, Luo D, Xu T, Sampath A, Lim SP, Canard B, Vasudevan SG. 2008. Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from dengue virus as a target. Antiviral Res. 80:94&#x2013;101. 10.1016/j.antiviral.2008.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2008.07.001</ArticleId><ArticleId IdType="pubmed">18674567</ArticleId></ArticleIdList></Reference><Reference><Citation>Bollati M, Alvarez K, Assenberg R, Baronti C, Canard B, Cook S, Coutard B, Decroly E, de Lamballerie X, Gould EA, Grard G, Grimes JM, Hilgenfeld R, Jansson AM, Malet H, Mancini EJ, Mastrangelo E, Mattevi A, Milani M, Moureau G, Neyts J, Owens RJ, Ren J, Selisko B, Speroni S, Steuber H, Stuart DI, Unge T, Bolognesi M. 2010. Structure and functionality in flavivirus NS-proteins: perspectives for drug design. Antiviral Res. 87:125&#x2013;148. 10.1016/j.antiviral.2009.11.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2009.11.009</ArticleId><ArticleId IdType="pmc">PMC3918146</ArticleId><ArticleId IdType="pubmed">19945487</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung D, Schroder K, White H, Fang NX, Stoermer MJ, Abbenante G, Martin JL, Young PR, Fairlie DP. 2001. Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors. J. Biol. Chem. 276:45762&#x2013;45771. 10.1074/jbc.M107360200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M107360200</ArticleId><ArticleId IdType="pubmed">11581268</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang CC, Hsieh YC, Lee SJ, Wu SH, Liao CL, Tsao CH, Chao YS, Chern JH, Wu CP, Yueh A. 2011. Novel dengue virus-specific NS2B/NS3 protease inhibitor, BP2109, discovered by a high-throughput screening assay. Antimicrob. Agents Chemother. 55:229&#x2013;238. 10.1128/AAC.00855-10</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00855-10</ArticleId><ArticleId IdType="pmc">PMC3019636</ArticleId><ArticleId IdType="pubmed">20937790</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng J, Li N, Liu H, Zuo Z, Liew OW, Xu W, Chen G, Tong X, Tang W, Zhu J, Zuo J, Jiang H, Yang CG, Li J, Zhu W. 2012. Discovery of novel small molecule inhibitors of dengue viral NS2B-NS3 protease using virtual screening and scaffold hopping. J. Med. Chem. 55:6278&#x2013;6293. 10.1021/jm300146f</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm300146f</ArticleId><ArticleId IdType="pubmed">22742496</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S, Li H, Shao X, Fan C, Ericksen B, Liu J, Chi C, Wang C. 2012. Critical effect of peptide cyclization on the potency of peptide inhibitors against dengue virus NS2B-NS3 protease. J. Med. Chem. 55:6881&#x2013;6887. 10.1021/jm300655h</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm300655h</ArticleId><ArticleId IdType="pubmed">22780881</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothan HA, Han HC, Ramasamy TS, Othman S, Rahman NA, Yusof R. 2012. Inhibition of dengue NS2B-NS3 protease and viral replication in Vero cells by recombinant retrocyclin-1. BMC Infect. Dis. 12:314. 10.1186/1471-2334-12-314</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-12-314</ArticleId><ArticleId IdType="pmc">PMC3575220</ArticleId><ArticleId IdType="pubmed">23171075</ArticleId></ArticleIdList></Reference><Reference><Citation>Chanprapaph S, Saparpakorn P, Sangma C, Niyomrattanakit P, Hannongbua S, Angsuthanasombat C, Katzenmeier G. 2005. Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sites. Biochem. Biophys. Res. Commun. 330:1237&#x2013;1246. 10.1016/j.bbrc.2005.03.107</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2005.03.107</ArticleId><ArticleId IdType="pubmed">15823576</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesh VK, Muller N, Judge K, Luan CH, Padmanabhan R, Murthy KH. 2005. Identification and characterization of nonsubstrate based inhibitors of the essential dengue and West Nile virus proteases. Bioorg. Med. Chem. 13:257&#x2013;264. 10.1016/j.bmc.2004.09.036</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2004.09.036</ArticleId><ArticleId IdType="pubmed">15582469</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiat TS, Pippen R, Yusof R, Ibrahim H, Khalid N, Rahman NA. 2006. Inhibitory activity of cyclohexenyl chalcone derivatives and flavonoids of fingerroot, Boesenbergia rotunda (L.), towards dengue-2 virus NS3 protease. Bioorg. Med. Chem. Lett. 16:3337&#x2013;3340. 10.1016/j.bmcl.2005.12.075</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2005.12.075</ArticleId><ArticleId IdType="pubmed">16621533</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Z, Patel SJ, Wang WL, Wang G, Chan WL, Rao KR, Alam J, Jeyaraj DA, Ngew X, Patel V, Beer D, Lim SP, Vasudevan SG, Keller TH. 2006. Peptide inhibitors of dengue virus NS3 protease. Part 1: warhead. Bioorg. Med. Chem. Lett. 16:36&#x2013;39. 10.1016/j.bmcl.2005.09.062</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2005.09.062</ArticleId><ArticleId IdType="pubmed">16246553</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Z, Patel SJ, Wang WL, Chan WL, Ranga Rao KR, Wang G, Ngew X, Patel V, Beer D, Knox JE, Ma NL, Ehrhardt C, Lim SP, Vasudevan SG, Keller TH. 2006. Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors. Bioorg. Med. Chem. Lett. 16:40&#x2013;43. 10.1016/j.bmcl.2005.09.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2005.09.049</ArticleId><ArticleId IdType="pubmed">16246563</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodenreider C, Beer D, Keller TH, Sonntag S, Wen D, Yap L, Yau YH, Shochat SG, Huang D, Zhou T, Caflisch A, Su XC, Ozawa K, Otting G, Vasudevan SG, Lescar J, Lim SP. 2009. A fluorescence quenching assay to discriminate between specific and nonspecific inhibitors of dengue virus protease. Anal. Biochem. 395:195&#x2013;204. 10.1016/j.ab.2009.08.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ab.2009.08.013</ArticleId><ArticleId IdType="pubmed">19682971</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomlinson SM, Malmstrom RD, Russo A, Mueller N, Pang YP, Watowich SJ. 2009. Structure-based discovery of dengue virus protease inhibitors. Antiviral Res. 82:110&#x2013;114. 10.1016/j.antiviral.2009.02.190</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2009.02.190</ArticleId><ArticleId IdType="pmc">PMC2680748</ArticleId><ArticleId IdType="pubmed">19428601</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrd CM, Grosenbach DW, Berhanu A, Dai D, Jones KF, Cardwell KB, Schneider C, Yang G, Tyavanagimatt S, Harver C, Wineinger KA, Page J, Stavale E, Stone MA, Fuller KP, Lovejoy C, Leeds JM, Hruby DE, Jordan R. 2013. Novel benzoxazole inhibitor of dengue virus replication that targets the NS3 helicase. Antimicrob. Agents Chemother. 57:1902&#x2013;1912. 10.1128/AAC.02251-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.02251-12</ArticleId><ArticleId IdType="pmc">PMC3623359</ArticleId><ArticleId IdType="pubmed">23403421</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu W, Gill T, Wang L, Du Y, Ye H, Qu X, Guo JT, Cuconati A, Zhao K, Block TM, Xu X, Chang J. 2012. Design, synthesis, and biological evaluation of N-alkylated deoxynojirimycin (DNJ) derivatives for the treatment of dengue virus infection. J. Med. Chem. 55:6061&#x2013;6075. 10.1021/jm300171v</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm300171v</ArticleId><ArticleId IdType="pmc">PMC3395807</ArticleId><ArticleId IdType="pubmed">22712544</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao B, Tong XK, Tang W, Li DW, He PL, Garcia JM, Zeng LM, Gao AH, Yang L, Li J, Nan FJ, Jacobs M, Altmeyer R, Zuo JP, Hu YH. 2012. Discovery and optimization of 2,4-diaminoquinazoline derivatives as a new class of potent dengue virus inhibitors. J. Med. Chem. 55:3135&#x2013;3143. 10.1021/jm2015952</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm2015952</ArticleId><ArticleId IdType="pubmed">22448770</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones CT, Patkar CG, Kuhn RJ. 2005. Construction and applications of yellow fever virus replicons. Virology 331:247&#x2013;259. 10.1016/j.virol.2004.10.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2004.10.034</ArticleId><ArticleId IdType="pubmed">15629769</ArticleId></ArticleIdList></Reference><Reference><Citation>Horscroft N, Lai VC, Cheney W, Yao N, Wu JZ, Hong Z, Zhong W. 2005. Replicon cell culture system as a valuable tool in antiviral drug discovery against hepatitis C virus. Antivir. Chem. Chemother. 16:1&#x2013;12</Citation><ArticleIdList><ArticleId IdType="pubmed">15739617</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice CM. 2011. New insights into HCV replication: potential antiviral targets. Top. Antivir. Med. 19:117&#x2013;120</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6148863</ArticleId><ArticleId IdType="pubmed">21946389</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariq H, Manzoor S, Parvaiz F, Javed F, Fatima K, Qadri I. 2012. An overview: in vitro models of HCV replication in different cell cultures. Infect. Genet. Evol. 12:13&#x2013;20. 10.1016/j.meegid.2011.10.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2011.10.009</ArticleId><ArticleId IdType="pubmed">22061839</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang PL, Gao M, Lin K, Liu Q, Villareal VA. 2011. Anti-HCV drugs in the pipeline. Curr. Opin. Virol. 1:607&#x2013;616. 10.1016/j.coviro.2011.10.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2011.10.019</ArticleId><ArticleId IdType="pmc">PMC3775341</ArticleId><ArticleId IdType="pubmed">22440918</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O'Boyle DR, II, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG. 2010. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:96&#x2013;100. 10.1038/nature08960</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08960</ArticleId><ArticleId IdType="pmc">PMC7094952</ArticleId><ArticleId IdType="pubmed">20410884</ArticleId></ArticleIdList></Reference><Reference><Citation>Einav S, Sobol HD, Gehrig E, Glenn JS. 2010. The hepatitis C virus (HCV) NS4B RNA binding inhibitor clemizole is highly synergistic with HCV protease inhibitors. J. Infect. Dis. 202:65&#x2013;74. 10.1086/653080</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/653080</ArticleId><ArticleId IdType="pmc">PMC3008401</ArticleId><ArticleId IdType="pubmed">20486856</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang X, Zhang M, Dayton AI. 2001. Development of dengue virus type 2 replicons capable of prolonged expression in host cells. BMC Microbiol. 1:18. 10.1186/1471-2180-1-18</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2180-1-18</ArticleId><ArticleId IdType="pmc">PMC56997</ArticleId><ArticleId IdType="pubmed">11580862</ArticleId></ArticleIdList></Reference><Reference><Citation>Puig-Basagoiti F, Tilgner M, Forshey BM, Philpott SM, Espina NG, Wentworth DE, Goebel SJ, Masters PS, Falgout B, Ren P, Ferguson DM, Shi PY. 2006. Triaryl pyrazoline compound inhibits flavivirus RNA replication. Antimicrob. Agents Chemother. 50:1320&#x2013;1329. 10.1128/AAC.50.4.1320-1329.2006</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.50.4.1320-1329.2006</ArticleId><ArticleId IdType="pmc">PMC1426921</ArticleId><ArticleId IdType="pubmed">16569847</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng CY, Gu F, Phong WY, Chen YL, Lim SP, Davidson A, Vasudevan SG. 2007. Construction and characterization of a stable subgenomic dengue virus type 2 replicon system for antiviral compound and siRNA testing. Antiviral Res. 76:222&#x2013;231. 10.1016/j.antiviral.2007.06.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2007.06.007</ArticleId><ArticleId IdType="pubmed">17662475</ArticleId></ArticleIdList></Reference><Reference><Citation>Masse N, Davidson A, Ferron F, Alvarez K, Jacobs M, Romette JL, Canard B, Guillemot JC. 2010. Dengue virus replicons: production of an interserotypic chimera and cell lines from different species, and establishment of a cell-based fluorescent assay to screen inhibitors, validated by the evaluation of ribavirin's activity. Antiviral Res. 86:296&#x2013;305. 10.1016/j.antiviral.2010.03.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2010.03.010</ArticleId><ArticleId IdType="pubmed">20307577</ArticleId></ArticleIdList></Reference><Reference><Citation>Qing M, Liu W, Yuan Z, Gu F, Shi PY. 2010. A high-throughput assay using dengue-1 virus-like particles for drug discovery. Antiviral Res. 86:163&#x2013;171. 10.1016/j.antiviral.2010.02.313</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2010.02.313</ArticleId><ArticleId IdType="pubmed">20153777</ArticleId></ArticleIdList></Reference><Reference><Citation>Shum D, Smith JL, Hirsch AJ, Bhinder B, Radu C, Stein DA, Nelson JA, Fruh K, Djaballah H. 2010. High-content assay to identify inhibitors of dengue virus infection. Assay Drug Dev. Tech. 8:553&#x2013;570. 10.1089/adt.2010.0321</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/adt.2010.0321</ArticleId><ArticleId IdType="pmc">PMC2962577</ArticleId><ArticleId IdType="pubmed">20973722</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie X, Wang QY, Xu HY, Qing M, Kramer L, Yuan Z, Shi PY. 2011. Inhibition of dengue virus by targeting viral NS4B protein. J. Virol. 85:11183&#x2013;11195. 10.1128/JVI.05468-11</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.05468-11</ArticleId><ArticleId IdType="pmc">PMC3194949</ArticleId><ArticleId IdType="pubmed">21865382</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu YC, Chen NC, Chen PC, Wang CC, Cheng WC, Wu HN. 2012. Identification of a small-molecule inhibitor of dengue virus using a replicon system. Arch. Virol. 157:681&#x2013;688. 10.1007/s00705-012-1224-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-012-1224-z</ArticleId><ArticleId IdType="pubmed">22249364</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens AJ, Gahan ME, Mahalingam S, Keller PA. 2009. The medicinal chemistry of dengue fever. J. Med. Chem. 52:7911&#x2013;7926. 10.1021/jm900652e</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm900652e</ArticleId><ArticleId IdType="pubmed">19739651</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YL, Liao CL, Chen LK, Yeh CT, Liu CI, Ma SH, Huang YY, Huang YL, Kao CL, King CC. 1998. Study of dengue virus infection in SCID mice engrafted with human K562 cells. J. Virol. 72:9729&#x2013;9737</Citation><ArticleIdList><ArticleId IdType="pmc">PMC110483</ArticleId><ArticleId IdType="pubmed">9811707</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LK, Lin YL, Liao CL, Lin CG, Huang YL, Yeh CT, Lai SC, Jan JT, Chin C. 1996. Generation and characterization of organ-tropism mutants of Japanese encephalitis virus in vivo and in vitro. Virology 223:79&#x2013;88. 10.1006/viro.1996.0457</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.1996.0457</ArticleId><ArticleId IdType="pubmed">8806542</ArticleId></ArticleIdList></Reference><Reference><Citation>Miroux B, Walker JE. 1996. Over-production of proteins in Escherichia coli: mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels. J. Mol. Biol. 260:289&#x2013;298. 10.1006/jmbi.1996.0399</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jmbi.1996.0399</ArticleId><ArticleId IdType="pubmed">8757792</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke D. 2000. Methods in yeast genetics: a Cold Spring Harbor Laboratory course manual, 2000 ed. Cold Spring Harbor Laboratory Press, Plainview, NY</Citation></Reference><Reference><Citation>Yang CC, Tsai MH, Hu HS, Pu SY, Wu RH, Wu SH, Lin HM, Song JS, Chao YS, Yueh A. 2013. Characterization of an efficient dengue virus replicon for development of assays of discovery of small molecules against dengue virus. Antiviral Res. 98:228&#x2013;241. 10.1016/j.antiviral.2013.03.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2013.03.001</ArticleId><ArticleId IdType="pubmed">23499649</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YL, Liu CC, Lei HY, Yeh TM, Lin YS, Chen RM, Liu HS. 2000. Infection of five human liver cell lines by dengue-2 virus. J. Med. Virol. 60:425&#x2013;431. 10.1002/(SICI)1096-9071(200004)60:4&lt;425::AID-JMV10&gt;3.0.CO;2-A</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-9071(200004)60:4&lt;425::AID-JMV10&gt;3.0.CO;2-A</ArticleId><ArticleId IdType="pubmed">10686026</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu SF, Lee CJ, Liao CL, Dwek RA, Zitzmann N, Lin YL. 2002. Antiviral effects of an iminosugar derivative on flavivirus infections. J. Virol. 76:3596&#x2013;3604. 10.1128/JVI.76.8.3596-3604.2002</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.76.8.3596-3604.2002</ArticleId><ArticleId IdType="pmc">PMC136089</ArticleId><ArticleId IdType="pubmed">11907199</ArticleId></ArticleIdList></Reference><Reference><Citation>Houng HH, Hritz D, Kanesa-thasan N. 2000. Quantitative detection of dengue 2 virus using fluorogenic RT-PCR based on 3&#x2032;-noncoding sequence. J. Virol. Methods 86:1&#x2013;11. 10.1016/S0166-0934(99)00166-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0166-0934(99)00166-4</ArticleId><ArticleId IdType="pubmed">10713370</ArticleId></ArticleIdList></Reference><Reference><Citation>Deas TS, Binduga-Gajewska I, Tilgner M, Ren P, Stein DA, Moulton HM, Iversen PL, Kauffman EB, Kramer LD, Shi PY. 2005. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J. Virol. 79:4599&#x2013;4609. 10.1128/JVI.79.8.4599-4609.2005</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.8.4599-4609.2005</ArticleId><ArticleId IdType="pmc">PMC1069577</ArticleId><ArticleId IdType="pubmed">15795246</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou G, Puig-Basagoiti F, Zhang B, Qing M, Chen L, Pankiewicz KW, Felczak K, Yuan Z, Shi PY. 2009. A single-amino acid substitution in West Nile virus 2K peptide between NS4A and NS4B confers resistance to lycorine, a flavivirus inhibitor. Virology 384:242&#x2013;252. 10.1016/j.virol.2008.11.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2008.11.003</ArticleId><ArticleId IdType="pmc">PMC5388927</ArticleId><ArticleId IdType="pubmed">19062063</ArticleId></ArticleIdList></Reference><Reference><Citation>Pu SY, Wu RH, Yang CC, Jao TM, Tsai MH, Wang JC, Lin HM, Chao YS, Yueh A. 2011. Successful propagation of flavivirus infectious cDNAs by a novel method to reduce the cryptic bacterial promoter activity of virus genomes. J. Virol. 85:2927&#x2013;2941. 10.1128/JVI.01986-10</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01986-10</ArticleId><ArticleId IdType="pmc">PMC3067970</ArticleId><ArticleId IdType="pubmed">21228244</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer M, Chan A, Dieckmann T, Honek J. 2012. Biochemical pharmacology, 1st ed. John Wiley &amp; Sons, Hoboken, NJ</Citation></Reference><Reference><Citation>Beran RK, Pyle AM. 2008. Hepatitis C viral NS3-4A protease activity is enhanced by the NS3 helicase. J. Biol. Chem. 283:29929&#x2013;29937. 10.1074/jbc.M804065200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M804065200</ArticleId><ArticleId IdType="pmc">PMC2573085</ArticleId><ArticleId IdType="pubmed">18723512</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao N, Reichert P, Taremi SS, Prosise WW, Weber PC. 1999. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 7:1353&#x2013;1363. 10.1016/S0969-2126(00)80025-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0969-2126(00)80025-8</ArticleId><ArticleId IdType="pubmed">10574797</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang CC, Huang ZS, Chiang PL, Chen CT, Wu HN. 2009. Analysis of the nucleoside triphosphatase, RNA triphosphatase, and unwinding activities of the helicase domain of dengue virus NS3 protein. FEBS Lett. 583:691&#x2013;696. 10.1016/j.febslet.2009.01.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2009.01.008</ArticleId><ArticleId IdType="pubmed">19166847</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>